• Home   /  
  • Archive by category "1"

5 Apb 6 Apb Comparison Essay

I have access to 5-apb and 6-apb from the same source. I thought it may be useful to show marquis test results of each for comparison.

First up is 5-apb. It is lighter in color and has a different smell. Not unpleasant. I would describe it as similar to 6-apb but with a sweeter note.

Next is an early batch of 6-apb.

A later batch 6-apb

All 3 next to each other:

The tests were done with new Marquis. Small quantity of each powder placed into a white porcelain coffee cup and 3 drops of marquis were added to each. The order from left to right is as above. 5-apb, older 6-apb and newer 6-apb

After 5 mins:

The 2 6-apb results were identical. Here is an example of one:

Here is the 5-apb result:

Observations are as follows. 5-apb produces a much darker result. When the liquid is in a puddle, it looks black. Swirl it around the edges and you will see a dark brown/green/yellow colouring. The 6-apb is a distinctive purple colour. Easily distinguishable from 5-apb. Upon swirling around the cup the colour remains consistently purple.

So, they look different, they smell different and they (5-apb and 6-apb powder) react differently towards marquis reagent.

Just for kicks, I tested an original batch BF pellet.

Adding marquis:
This also gave the same purple colour change as 6-apb powder. It was less intense due to the presence of the binder, meaning less 6-apb was present to react with the marquis.

Hope this may be of use. I have higher res-images available and will post them if required. These should give you an idea at least.

Molecular structure of 6-APB
6-APB, "Benzofury"

6-(2-Aminopropyl)benzofuran (also known as 6-APB or by the brand-name Benzofury) is a novel entactogen substance of the benzofuran class. It produces long-lived entactogenic and stimulant effects such as anxiety suppression, disinhibition, muscle relaxation, and euphoria when administered. It is structurally related to entactogens like MDA, MDMA, 5-APB, and 5-MAPB.

6-APB was first synthesized in 1993 by psychedelic chemist and researcher David E. Nichols as a potential non-neurotoxic alternative to MDMA.[1] However, it did not come into popular recreational use until over a decade later, where it briefly entered the rave scene and global research chemicals market. It was sold along with other novel benzofuran entactogens under the name "Benzofury" before its sale and import were subsequently banned.[citation needed]

Very little data exists about the pharmacological properties, metabolism, and toxicity of 6-APB, and it has only a brief history of human usage. It has been commonly marketed alongside research chemicalentactogens like 5-MAPB and 5-APB as a legal, grey-market alternative to MDMA, and is typically commercially distributed by online research chemical vendors. It is highly advised to use harm reduction practices if using this substance.

History and culture

This History and Culture section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

The synthesis of 6-APB was first reported by a team led by the medicinal chemist and psychedelic researcher David E. Nichols at Purdue University. They were examining the role of the MDA dioxle ring structure in interacting with serotonergic neurons. It was also partly an effort to find an alternative to MDMA, which was gaining recognition as a potentially useful adjunct in psychotherapy, but was also being linked to neurotoxic effects.[1]

Human usage was not documented until 2010, when it emerged for sale on the research chemical market. It was particularly prominent in the UK "legal highs" market, where it was sold under the name "Benzofury".

On June 10, 2013 6-APB and a number of analogues were classified as Temporary Class Drugs in the UK following an ACMD recommendation.[2] On November 28, 2013 the ACMD recommended that 6-APB and related benzofurans should become Class B, Schedule 1 substances. On March 5, 2014 the UK Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[3]


6-APB, also known as 6-(2-aminopropyl)benzofuran, is a synthetic molecule of the benzofuran class. The benzofuran class of substances are members of the amphetamine and phenylethylamine classes. Molecules of this class contain a phenethylamine core bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. 6-APB does not contain a methyl substitution on RN. It is composed of an an oxygen-substituted benzofuran ring fused at R3 and R4 of the phenyl ring.

Notably, 6-APB shares this benzofuran ring with related compounds such as 5-APB, 5-MAPB, and 6-MAPB.

Three distinct batches have been in circulation since its initial release to markets. Originally, only hydrochloride was available, and its dosage range shared characteristics most similar to that of MDA in terms of dose-response. However, succinate and fumarate batches both entered the market, and have very different effects by weight, and vastly different loose bulk densities.

Effect ((oral) Dosage (HCl) Dosage (Succinate) Dosage (Fumarate) MDMA (HCl)
Threshold 10-40 mg 40-80 mg 10-30 mg 20-40 mg
Light 40-75 mg 80-160 mg 30-60 mg 40-70 mg
Common 75-125 mg 160-220 mg 60-90 mg 70-140 mg
Strong 125-150 mg 220-250 mg 90-120 mg 140-180 mg
Heavy 150 mg + 250 mg + 120 mg + 180 mg +


6-APB is a serotonin–norepinephrine–dopaminereuptake inhibitor (SNDRI) with Ki values of 117, 150, and 2698 nM for the norepinephrine transporter (NET), dopamine transporter (DAT), and serotonin transporter (SERT), respectively.[4] 6-APB also possesses additional activity as a releasing agent of these monoamine neurotransmitters.[5]

6-APB is a potent full agonist of the serotonin 5-HT2B receptor (Ki = 3.7 nM)[4], with higher affinity for this target than any other site.[6] Moreover, unlike MDMA, 6-APB shows 100-fold selectivity for the 5-HT2B receptor over the 5-HT2A and 5-HT2C receptors.[6][7]

Aside from the 5-HT2B receptor, 6-APB has also been found to bind with high affinity to the α2C-adrenergic receptor subtype (Ki = 45 nM), although the clinical significance of this action is unknown.[4]

The potent agonism of the 5-HT2B receptor makes it likely that 6-APB would be cardiotoxic with chronic or long-term use, as seen with other 5-HT2B receptor agonists such as the withdrawn serotonergic anorectic fenfluramine.[4][8]

The monoamine neurotransmitters known as serotonin, dopamine and noradrenaline are the global neurotransmitters that modulate the brain's ability to feel pleasure, motivation, reward, planning, attention, and focus. When their reuptake is inhibited or their release is promoted, these neurotransmitters accumulate in the synaptic cleft (gaps between neurons) to non-ordinary levels, which makes them able to be reused. The result is neuronal activation at a multitude of brain regions which has the net result of producing a combination of stimulating, relaxing, disinhibiting and euphoric effects.[9]

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWikicontributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

    • Stimulation & Sedation - In terms of its effects on the user's physical energy levels, 6-APB is commonly considered to have the paradoxical ability to both be stimulating as well as sedating and relaxing. Overall, it is thought to be far less energetic than MDMA or MDA and tends to exert more of a pronounced "stoning" or "couch-locking" effect. The particular style of stimulation which 6-APB presents is far less forceful in a way that can be compared to psychedelics like mescaline.
    • Spontaneous physical sensations - The "body high" of 6-APB can be described as a moderate to powerful warm, euphoric tingling sensation that radiates throughout the entire body. It is capable of becoming overwhelmingly pleasurable at higher doses to the point of immobilizing the user. This sensation maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
    • Tactile enhancement
    • Bodily control enhancement
    • Stamina enhancement
    • Temperature regulation suppression
      • Increased bodily temperature - As 6-APB is a serotonin releasing agent, a rise in core body and brain temperature tends to be high and consistent throughout the experience. Caution must be taken as too high of a dose can result in the dysregulation of the brain's ability to regulate its internal core temperature. 6-APB is commonly reported to having a similar hyperthermia to MDA and MDMA, but slightly warmer than either. Serotonin syndrome, a potentially fatal condition, presents this effect to dangerous levels.
    • Vibrating vision - At common to high doses, a person's eyeballs may begin to spontaneously wiggle back and forth in a rapid motion, causing the vision to become blurry and temporarily out of focus. This is a condition known as nystagmus.
    • Abnormal heartbeat
    • Increased heart rate
    • Increased blood pressure
    • Increased perspiration
    • Dehydration - Feelings of dry mouth and dehydration are a universal experience with this class of compounds; this effect is a product of an increased heart rate and bodily metabolism. While it is important to avoid becoming dehydrated (especially when out dancing in a hot environment) there have been some notable cases of users suffering from water intoxication through over-drinking (to compensate). It is therefore advised that users be mindful of their water intake and avoid over-drinking.
    • Dry mouth
    • Difficulty urinating - Higher doses of 6-APB can result in an overall difficulty when it comes to urination. This is an effect that is completely temporary and harmless. It is due to 6-APB’s promotion of the release of anti-diuretic hormone (ADH); ADH is responsible for regulating urination. This effect can be lessened by simply relaxing, but can be significantly relieved by placing a hot flannel over the genitals to warm them up and encourage blood flow to the region.
    • Appetite suppression
    • Pupil dilation
    • Excessive yawning
    • Temporary erectile dysfunction
    • Teeth grinding - This is usually only present at moderate to higher doses and is similar to what one might experience from MDMA or MDA.
    • Seizure - This is a rare effect but are thought to be able to occur in those who are predisposed to them, especially when taking overly strong doses or redosing while in physically taxing conditions such as being dehydrated, fatigued, undernourished, or overheated.[citation needed]
  • The visual effects of 6-APB have an occurrence rating that is more selective and less consistent than any of the traditional psychedelics. The effects can never be guaranteed to manifest themselves, but are the most likely to occur with high doses, towards the end of the experience and particularly if the user has been smoking cannabis. They are also more likely to occur if the user has prior experience with psychedelics, but also remain entirely possible for those who have never tried them as well. Unlike MDMA, 6-APB can directly induce mild to moderate psychedelic visual effects due to its ability to partially agonize the 5-HT2A receptor, which makes it qualitatively more similar to MDA.[citation needed]


    6-APB presents an array of visual enhancements which are mild in comparison to traditional psychedelics, but still distinctively present. These generally include:


    • Tracers - Tracers are most similar to those found with MDA, with longer sections of continuity before a slight discontinuity. This effect is most prominent with LED hoops.
    • Symmetrical texture repetition


    The visual geometry of 6-APB experience can be described as more similar in appearance to that of mescaline than LSD or psilocin. It can be comprehensively described through its variations as primarily intricate in complexity, abstract in form, organic in style, structured in organization, dimly lit in lighting, mostly monotone in colour with blues and greys, glossy in shading, sharp in edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in-depth and consistent in intensity. At higher doses, they are significantly more likely to result in states of level 8A visual geometry over level 8B.

    Hallucinatory states

    At high to heavy doses, 6-APB is capable of producing a unique range of low and high-level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects are far more common during the offset of the experience and commonly include:

    • Transformations
    • External hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - This effect is very similar to the same experience found within deliriants, but does not manifest itself consistently and usually happens only at high doses. It can be comprehensively described through its variations as delirious in believability, autonomous in controllability and solid in style. They usually follow themes of memory replays and semi-realistic or expected events. For example, people could be casually holding objects or performing actions which one would expect them to be in real life before disappearing and dissolving under further inspection. Common examples of this include seeing people wearing glasses or hats when they are not and mistaking faces of your friends for random people, and objects as human beings or animals.
    • Internal hallucinations - The internal hallucinations which 6-APB induce are mostly only present as spontaneous breakthroughs at extremely high doses. This effect's variations are delirious in believability, interactive in style, new experiences in content, autonomous in controllability and solid in appearance. The most common way in which they manifest themselves are through hypnagogic scenarios which the user may experience as they are drifting off to sleep after a night of use; these can usually be described as memory replay from the previous several hours. These are short and fleeting, but frequent and completely believable and convincing as they happen. In terms of the theme, they often take the form of conversations with the people who were with you or instead manifest themselves as bizarre and extremely nonsensical plots.
    • Peripheral information misinterpretation
  • The cognitive effects of 6-APB can be broken down into several components which progressively intensify proportional to dosage. The general head space of 6-APB is described by many as one of moderate mental stimulation, feelings of love, openness or empathy, and a powerful sense of contentedness and euphoria. It displays a large number of typical psychedelic, entactogenic and stimulant cognitive effects. The most prominent of these cognitive effects generally include:
    • Anxiety suppression
    • Disinhibition
    • Cognitive euphoria - Strong emotional euphoria and feelings of happiness are present within 6-APB and are likely a direct result of serotonin and dopamine release.
    • Empathy, affection, and sociability enhancement - This particular effect is more consistent, pronounced, powerful and therapeutic with 6-APB than any other known substance. It is the most obvious and noticeable effect within any 6-APB experience and dominates the head space. With time, repeated use, and improper spacing, however, this effect becomes severely diminished as the perspective it instills becomes fully imprinted, making it, so users feel merely speedy and scattered with no new found urges to communicate or bond with others.
    • Novelty enhancement
    • Creativity enhancement
    • Focus enhancement - This component is most effective at low to moderate doses as anything higher will usually impair concentration.
    • Immersion enhancement
    • Motivation enhancement
    • 'Effect: Memory Suppression - This effect is thought to be mild in comparison with other substances such as alcohol, and classical benzodiazepines, lending to a more "spaced-out" feeling, best described as episodic memory.
    • Emotion enhancement
    • Increased music appreciation
    • Personal meaning enhancement
    • Increased sense of humor
    • Compulsive redosing - Due to its potential euphoria-inducing effects, there is the potential for 6-APB to encourage compulsive redosing, much like with MDMA or MDA. Due to the length of the experience, many find this need to be less pressing. Due to its unknown toxicity profile and reports of a severely amplified offset ("come down") and after effects, it is highly discouraged to redose this substance. It is thought to share some commonalities with DOM and other related compounds in this sense.
    • Increased libido
    • Mindfulness
    • Thought acceleration
    • Time distortion - Strong feelings of time compression are common within 6-APB and alter the experience of time quite noticeably, although not to the same extent as typically reported with MDMA.
    • Wakefulness - This component is present, but to a noticeably lesser degree than MDMA. Users often report being heavily sedated or "floored" compared to typical stimulants.
    • Existential self-realization - Although this effect is present, it is not quite as pronounced or as consistent when compared to other hallucinogens such as mescaline, LSD or MXE. Due to the relative calmness and lack of chaotic energy that 6-APB possesses relative to MDMA, however, this combined with its extended duration may make it a better therapeutic agent and can be thought of as lying closer to the spectrum of mescaline than MDMA.
    • Unity and interconnectedness - While rare, experiences of unity, oneness and interconnectedness may occur on 6-APB. This component most reliably manifests itself at high doses within large crowds at raves and musical events in the form of "becoming one with the crowd."

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its similarity to MDMA, it is likely that the administration of repeated or high dosages of 6-APB may be both neurotoxic and cardiotoxic[10][11] in some form.

The exact toxic dosage is unknown. It is strongly recommended that one use harm reduction practices when using this substance.

Short-term health concerns

Short-term physical health risks of 6-APB consumption include dehydration, insomnia, and hyperthermia (overheating).[12] Continuous activity without sufficient rest or rehydration may cause body temperature to rise to dangerous levels, and loss of fluid via excessive sweating puts the body at further risk as the stimulating and euphoric properties of the substance may render the user oblivious to their energy expenditure for quite some time. Diuretics such as alcohol may exacerbate these risks further.

Although it has not been formally studied, small changes in ambient temperature may cause large changes in 6-APB-induced serotonergic neurotoxicity as is the case with MDMA.[13][14]

Long-term health concerns

The neurotoxicity of 6-APB is subject to ongoing discussion. It was specifically designed to be less neurotoxic than MDA or MDMA by circumventing the production of certain metabolic byproducts thought to underlie their toxicity (specifically alpha-methyl-dopamine).[citation needed] Although it is likely to be physically safe to try in a responsible context, it is completely possible that the administration of repeated or high dosages of 6-APB could result in neurotoxicity in some form, presenting as deficits in cognitive, affective and psychomotor function.

As with MDMA, the long-term, heavy usage of 6-APB (i.e. regular daily or weekly usage) is likely cardiotoxic and may lead to valvulopathy (heart valve issues) via its significant affinity for the 5-HT2B receptor.[15][16]

Tolerance and addiction potential

As with other stimulants, the chronic use of 6-APB can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

As a potent releaser of serotonin, tolerance builds quickly with prolonged and repeated use to the point that the substance eventually loses any positive effects and instead leaves the user in an uncomfortable state of anxious, dysphoric stimulation. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3-4 weeks for the tolerance to be reduced to half and 6-8 weeks to be back at baseline (in the absence of further consumption). 6-APB presents cross-tolerance with all dopaminergicstimulants, meaning that after the consumption of 6-APB all stimulants will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

  • 25x-NBOMe - Both the NBOMe series and this compound induce powerful stimulation and their interaction may cause severe side effects. These can include thought loops, seizures, increased blood pressure, vasoconstriction, increased heart rate, and heart failure (in extreme cases).
  • Alcohol - It is dangerous to combine alcohol, a depressant, with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of alcohol which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of alcohol will be significantly increased, leading to intensified disinhibition as well as respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - This combination may cause increased heart rate and panic attacks.
  • MXE - Increased heart rate and blood pressure may occur.
  • Tramadol - This combination can increase the risk of seizures.
  • MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, 2C-T-2, 2C-T-7, αMT, and some antidepressants.[17]
  • Stimulants - The potential neurotoxic effects of 6-APB may be significantly increased when combined with other stimulants.[citation needed]
  • Cocaine - This combination may cause severe strain on the heart, potentially resulting in a heart attack or stroke.

Serotonin syndrome risk

Combinations in the list below may increase the amount of neurotransmitters such as serotonin and dopamine to dangerous or even fatal levels.

There is an increased risk of serotonin syndrome when 6-APB is taken with many antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).[citation needed] Additionally, if 6-APB is taken with SSRIs and SNRIs, it is likely to be significantly less effective if it produces any discernible effects at all.

Legal status

  • Australia and New Zealand: Certain countries contain a "substantially similar" catch-all clause in their drug law, such as New Zealand and Australia. This includes 6-APB as it is similar in chemical structure to the class A drug MDA, meaning 6-APB may be viewed as a controlled substance analogue in these jurisdictions.[citation needed]
  • Canada: 6-APB is Schedule III in Canada as it is an analogue of MDA. The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.[citation needed]
  • Germany: 6-APB is illegal in Germany.[19]
  • Italy: 6-APB is illegal in Italy.[20]
  • Sweden: 6-APB is prohibited in Sweden as a "health hazard" as of 2009.[citation needed]
  • United Kingdom: On June 10, 2013, 6-APB and some analogues were classified as Temporary Class Drugs in the U.K. following an ACMD recommendation. On March 5, 2014, the U.K. Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[21]
  • United States: 6-APB is unscheduled in the United States, but not currently approved by the Food and Drug Administration for human consumption.[citation needed]

See also

External links



  1. 1.01.1Monte, A. P., Marona-Lewicka, D., Cozzi, N. V., & Nichols, D. E. (1993). Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogs of 3, 4-(methylenedioxy) amphetamine. Journal of Medicinal Chemistry, 36(23), 3700-3706. https://doi.org/10.1021/jm00075a027
  2. ↑Advisory Council on the Misuse of Drugs, Jeremy Browne (4 June 2013). "Temporary class drug order on benzofury and NBOMe compounds - letter from ACMD". GOV.UK.
  3. ↑UK Home Office (28 April 2014). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". The National Archives.
  4. Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL (2013). "Neurochemical profiles of some novel psychoactive substances". Eur. J. Pharmacol. 700 (1-3): 147–51. PMID 23261499. https://doi.org10.1016/j.ejphar.2012.12.006
  5. ↑ Rickli A, Kopf S, Hoener MC, Liechti ME (2015). "Pharmacological profile of novel psychoactive benzofurans". Br. J. Pharmacol. 172 (13): 3412–25. PMID 25765500. https://doi.org/10.1111/bph.13128
  6. 6.06.1Canal CE, Murnane KS (2017). "The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens". J. Psychopharmacol. (Oxford). 31 (1): 127–143. PMID 27903793. https://doi.org/10.1177/0269881116677104
  7. ↑US patent 7045545, Karin Briner, Joseph Paul Burkhart, Timothy Paul Burkholder, Matthew Joseph Fisher, William Harlan Gritton, Daniel Timothy Kohlman, Sidney Xi Liang, Shawn Christopher Miller, Jeffrey Thomas Mullaney, Yao-Chang Xu, Yanping Xu, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 19 January 2000, issued 16 May 2006
  8. ↑Advisory Council on the Misuse of Drugs, Jeremy Browne (4 June 2013). "Temporary class drug order on benzofury and NBOMe compounds - letter from ACMD". GOV.UK.
  9. ↑New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140
  10. ↑Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full
  11. ↑Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805
  12. ↑Drug-induced hyperthermia | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.1993.tb07423.x/abstract;jsessionid=FC30A9B157A2BAFC81048D8595714565.f02t03
  13. ↑(PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9634574
  14. ↑Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population | http://jop.sagepub.com/content/20/3/400
  15. ↑Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full
  16. ↑Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805
  17. ↑Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  18. ↑Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  19. "Anlage II BtMG - Einzelnorm)". Retrieved 2018-01-12. 
  20. ↑http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
  21. ↑http://www.legislation.gov.uk/uksi/2014/1106/contents/made

One thought on “5 Apb 6 Apb Comparison Essay

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *